Carolina Bernhardt

Short-Term Assignment Hidradenitis suppurativa is a painful long-term skin disease that causes abscesses and scarring on the skin – usually around the groin, buttocks, breasts and armpits. It's not known exactly what causes HS. An estimated 1% of the population has HS, but this may be an underestimate as some people may be too embarrassed to seek diagnosis and treatment. Source: http://www.nhs.uk/conditions/hidradenitis-suppurativa/Pages/Introduction.aspx

Achievements (extract): pre-launch and launch of new Humira® indications and label extensions in the field of gastroenterology; management and dvelopment of direct report (Junior Product Manager); active member in cross-functional task forces (Accounting, Human Ressources) aiming to improve internal processes

Responsible for the following in Austria marketed Rx-brands: Bone Portfolio: Reclast®/Aclasta® (zoledronic acid/zoledronic acid 5 mg): osteoporosis Auto-Inflammatory Portfolio: Ilaris® (canakinumab) (biological, orphan drug): Cryopyrin-Associated Periodic Syndrome (CAPS) Respiratory portfolio: Xolair® (omalizumab) (Biologic): severe allergic asthma Onbrez® (indacaterol): COPD Tobi® (tobramycin): cystic fibrosis Foradil® (formoterol) Miflonide® (budesonid) Other: Elidel® (pimecrolimus c

Achievements (extract): ˗ Developing, implementing and following-up on market- and product strategies for Plavix® (clopidogrel bisulfate) indicated for the reduction of atherothrombotic events to ensure market growth and market share; ˗ Preparing, planning and executing the brand’s budget; ˗ Monitoring the cardiovascular market as well as competitors’ activities; ˗ Identifying market trends and interpreting market research data in order to design effective marketing activities; ˗ Developing and rolli

Special company leave in context of merger

Achievements (extract): Developing and executing pre-launch and launch strategies for the introduction of Alvesco® (ciclesonide inhalation aerosol) indicated for the treatment of mild-to-moderate asthma (adults) on the Canadian market in September 2006, in particular: Supporting the development of effective launch brand plans for Omnaris® (ciclesonide nasal spray) and Daxas® (roflumilast) indicated for the treatment of allergic rhinitis and chronic obstructive pulmonary disease respectively

Achievements (extract): ˗ Promoting prescription drugs in the field of gastroenterology (Pantoloc® & Panto IV®, pantoprazole) and pain management (Maxalt®, rizatriptan benzoate) to GPs, specialists, hospitals and pharmacies located in South-West Ontario; ˗ Winner of the ‘Region of the Year 2003’ award;

Achievements (extract): ˗ Developing and implementing product- and market strategies; ˗ Supporting budget planning and control; ˗ Conducting sales forecasting; ˗ Monitoring markets and competitors; ˗ Co-ordinating operative marketing measures and activities

Achievements (extract): ˗ Developing marketing strategies and tactics; ˗ Conducting market and competitor analyses on corporate and local level; ˗ Establishing customer targeting system at the Belgian affiliate

Summer Semester Abroad: Copenhagen Business School (DK) Thesis: “Critical Success Factors for the Launch of Innovative Functional Foods and Drinks” Degree: Master of Business Administration Award: Distinction

Department of Marketing / Postgraduate Programmes Dissertation: “The Implementation of Customer Relationship Management in the Pharmaceutical Industry"

in co-operation with University of California at Berkeley, Berkeley (USA)

Field of studies: Global Business Studies Majors: Marketing, Management Studies, Controlling, Corporate Finance Thesis: “Category Management in Retailing”